Asset Details
Do you wish to reserve the book?
2022-RA-425-ESGO L1CAM as a predictive factor in early-stage cervical cancer patients
Hey, we have placed the reservation for you!
By the way, why not check out events that you can attend while you pick your title.
Oops! Something went wrong.
Looks like we were not able to place the reservation. Kindly try again later.
Are you sure you want to remove the book from the shelf?
2022-RA-425-ESGO L1CAM as a predictive factor in early-stage cervical cancer patients
Do you wish to request the book?
2022-RA-425-ESGO L1CAM as a predictive factor in early-stage cervical cancer patients
Please be aware that the book you have requested cannot be checked out. If you would like to checkout this book, you can reserve another copy
We have requested the book for you!
Your request is successful and it will be processed during the Library working hours. Please check the status of your request in My Requests.
Oops! Something went wrong.
Looks like we were not able to place your request. Kindly try again later.
Journal Article
2022-RA-425-ESGO L1CAM as a predictive factor in early-stage cervical cancer patients
2022
Overview
Introduction/BackgroundL1 cell adhesion molecule (L1CAM) belongs to the immunoglobulin superfamily of cell adhesion molecules and promotes cell proliferation, invasion, and metastasis. We aimed to study L1CAM expression in early-stage cervical cancer patients and assess its relationship to lymphovascular invasion (LVSI), histological type, degree of differentiation, tumor size, and lymph node involvement.MethodologyWe study the patients with cervical cancer who underwent surgery in our department (2007 – 2017). An immunohistochemical examination of L1CAM expression was provided. Those in which the presence of L1CAM was confirmed in more than 10% of tumor cells were marked as positive. We enrolled in total 187 patients in stages FIGO I and II. The histological tumor types were adenocarcinoma 20, adenosquamous 14, and squamous carcinoma 153. And grading distribution was 46 tumors in grade 1, 106 in grade 2, and 33 in grade 3. We confirm up to 2 cm in 71 tumors and 116 tumors over 2 cm. LVSI was evident in 67 tumors. Pelvic lymphadenectomy was performed in 169 patients; positive metastasis was in 38.ResultsL1CAM expression was positive in 39 (20.9%) tumors. We observed a significant difference in L1CAM expression in adenocarcinoma and adenosquamous carcinoma compared to squamous carcinoma (p=0.001). We noticed a difference in tumor size greater than or equal to 2 cm (p=0.005). L1CAM expression did not affect the degree of differentiation and the presence of LVSI (p=0.521; p=0.115, respectively). We also did not observe a difference in L1CAM expression regarding pelvic lymph node involvement (p=0.949).Abstract 2022-RA-425-ESGO Table 1The clinicopathological study group distribution in relation to the LICAM statusAbstract 2022-RA-425-ESGO Figure 1The clinicopathological study group distribution in relation to the L1CAM statusConclusionOur study did not confirm the increased L1CAM expression in cervical cancer as an adverse prognostic factor for LSVI, grade, and pelvic lymph node involvement. However, a significant relationship was seen between L1CAM expression, histological type of tumor, and its size. The study was supported by grant 24/RVO-FNOs/2020
Publisher
BMJ Publishing Group Ltd,Elsevier Inc,Elsevier Limited
Subject
